Sanofi and BMS's Combination Antiplatelet Agent, DuoPlavin, Receives EMA Approval for European Market
Innovative Single-Tablet Dual Antiplatelet Therapy
Sanofi (SAN) and Bristol Myers Squibb (BMY) jointly developed DuoPlavin, which received marketing authorization from the European Medicines Agency (EMA) on March 15, 2010. This drug is a combination therapy that combines clopidogrel, which selectively blocks the platelet ADP receptor (P2Y12), and acetylsalicylic acid (aspirin), which inhibits the COX-1 enzyme, into a single tablet. In dual antiplatelet therapy (DAPT) for preventing recurrent events in patients with cardiovascular disease, poor adherence due to the need to take multiple medications has been a persistent limitation. This approval of the combination therapy is clinically significant in that it improves the convenience for patients who previously took individual medications separately, thereby increasing treatment adherence and reducing the risk of recurrent thromboembolic events.
Efficacy Proven Through Large-Scale Landmark Clinical Data
This EMA approval was based on bioequivalence assessments between the individual components and the combination product, as well as the results of a large-scale landmark clinical trial. In the CURE trial, which involved approximately 12,000 patients, the combination therapy of clopidogrel and aspirin significantly reduced the risk of cardiovascular death, myocardial infarction, and stroke by 20% (Hazard Ratio 0.80) compared to aspirin monotherapy. Furthermore, the COMMIT trial, which involved more than 45,000 patients, also demonstrated a 9% reduction in the risk of death and recurrent myocardial infarction, further confirming its strong clinical efficacy. Because the U.S. Food and Drug Administration (FDA) has not approved the combination of clopidogrel and aspirin, this EMA decision is interpreted as reflecting a unique patient management paradigm in the European market.
Defensive Strategy for the Original Brand in Response to Patent Expiration
Plavix, the original blockbuster drug for clopidogrel, had annual global sales of approximately $9.4 billion (USD), but with the expiration of its patent, it faced intense competition from low-cost generic drugs. To overcome this impending sales cliff, Sanofi and BMS adopted a smart product life cycle (PLC) management strategy to proactively switch existing Plavix patients to the combination therapy, DuoPlavin. By targeting patients who are already stably taking the individual components, they aim to defend their prescription share and maximize the value of the original brand. This can be an excellent financial defense strategy that minimizes R&D costs while circumventing patent barriers.
Diversified Competitive Landscape with Next-Generation Drugs and Generics
Currently, the global antiplatelet drug market is rapidly changing, with the emergence of generic products that emphasize price competitiveness, as well as next-generation, more potent drugs. Daiichi Sankyo's prasugrel (brand name Effient) has already been approved in Europe, and AstraZeneca's ticagrelor (brand name Brilinta) is about to be launched. These new drugs boast faster and more potent antiplatelet effects than clopidogrel, and will inevitably pose a direct threat to DuoPlavin's market position. Ultimately, the key to DuoPlavin's future commercial success will be how well it can convince national health authorities of the cost-effectiveness of improved medication adherence in price negotiations.
This EMA approval of DuoPlavin represents a successful defensive R&D case, responding to the patent expiration of Plavix, which had annual sales of $9.4 billion, by minimizing R&D costs and successfully extending the product life cycle. It achieved approval by using bioequivalence data alone to replace Phase 3 clinical trials, and can leverage strong marketing based on the 20% reduction in cardiovascular risk demonstrated in the CURE and COMMIT trials. In the short term, it can be expected to improve medication adherence and prevent prescription loss, providing a generic defense effect. However, in the medium to long term, it will inevitably face competition from Daiichi Sankyo's prasugrel, which has already entered the market, and AstraZeneca's ticagrelor, which is about to be approved, both of which are more potent next-generation therapies. Therefore, in the global $9 billion antiplatelet drug market, demonstrating the cost-effectiveness of the combination formulation and the speed of reimbursement listing in each European country will be key variables in determining long-term sales defense.
Source: EMA (ema)